A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation

Yasin Kokoye, Ivan Ivanov, Qiufang Cheng, Anton Matafonov, S. Kent Dickeson, Shauna Mason, Daniel J. Sexton, Thomas Renné, Keith McCrae, Edward P. Feener, David Gailani

    Research output: Contribution to journalArticle

    23 Citations (Scopus)

    Abstract

    Studies with animal models implicate the plasma proteases factor XIIa (FXIIa) and α-kallikrein in arterial and venous thrombosis. As congenital deficiencies of factor XII (FXII) or prekallikrein (PK), the zymogens of FXIIa and α-kallikrein respectively, do not cause bleeding disorders, inhibition of these enzymes may have therapeutic benefit without compromising hemostasis. The relative contributions of FXIIa and α-kallikrein to thrombosis in animal models are not clear. We compared mice lacking FXII or PK to wild type mice in established models of arterial thrombosis. Wild type mice developed carotid artery occlusion when the vessel was exposed to a 3.5% solution of ferric chloride (FeCl3). FXII-deficient mice were resistant to occlusion at 5% FeCl3 and partially resistant at 10% FeCl3. PK-deficient mice were resistant at 3.5% FeCl3 and partially resistant at 5% FeCl3. Mice lacking high molecular weight kininogen, a cofactor for PK activation and activity, were also partially resistant to thrombosis at 5% FeCl3. Induction of carotid artery thrombosis with Rose Bengal was delayed in FXII-deficient mice compared to wild type or PK-deficient animals. In human plasma supplemented with silica, DNA or collagen to induce contact activation, an antibody to the FXIIa active site was more effective at preventing thrombin generation than an antibody to the α-kallikrein active site. Similarly, the FXIIa antibody was more effective at reducing fibrin formation in human blood flowing through collagen coated-tubes. The findings suggest that inhibitors of FXIIa will have more potent anti-thrombotic effects than inhibitors of α-kallikrein.

    Original languageEnglish
    Pages (from-to)118-124
    Number of pages7
    JournalThrombosis Research
    Volume140
    DOIs
    Publication statusPublished - 1 Apr 2016

    Fingerprint

    Factor XII Deficiency
    Factor XIIa
    Prekallikrein
    Kallikreins
    Thrombosis
    Factor XII
    Antibodies
    Catalytic Domain
    Collagen
    Animal Models
    Carotid Artery Thrombosis
    High Molecular Weight Kininogens
    Rose Bengal
    Enzyme Precursors
    Prekallikrein Deficiency
    Hemostasis
    Fibrin
    Carotid Arteries
    Thrombin
    Venous Thrombosis

    Keywords

    • Factor XII
    • Factor XIIa
    • Prekallikrein
    • Thrombosis
    • α-Kallikrein

    ASJC Scopus subject areas

    • Hematology

    Cite this

    Kokoye, Y., Ivanov, I., Cheng, Q., Matafonov, A., Dickeson, S. K., Mason, S., ... Gailani, D. (2016). A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation. Thrombosis Research, 140, 118-124. https://doi.org/10.1016/j.thromres.2016.02.020

    A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation. / Kokoye, Yasin; Ivanov, Ivan; Cheng, Qiufang; Matafonov, Anton; Dickeson, S. Kent; Mason, Shauna; Sexton, Daniel J.; Renné, Thomas; McCrae, Keith; Feener, Edward P.; Gailani, David.

    In: Thrombosis Research, Vol. 140, 01.04.2016, p. 118-124.

    Research output: Contribution to journalArticle

    Kokoye, Y, Ivanov, I, Cheng, Q, Matafonov, A, Dickeson, SK, Mason, S, Sexton, DJ, Renné, T, McCrae, K, Feener, EP & Gailani, D 2016, 'A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation', Thrombosis Research, vol. 140, pp. 118-124. https://doi.org/10.1016/j.thromres.2016.02.020
    Kokoye, Yasin ; Ivanov, Ivan ; Cheng, Qiufang ; Matafonov, Anton ; Dickeson, S. Kent ; Mason, Shauna ; Sexton, Daniel J. ; Renné, Thomas ; McCrae, Keith ; Feener, Edward P. ; Gailani, David. / A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation. In: Thrombosis Research. 2016 ; Vol. 140. pp. 118-124.
    @article{27e32f223d8441b2bd282ecca429c89d,
    title = "A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation",
    abstract = "Studies with animal models implicate the plasma proteases factor XIIa (FXIIa) and α-kallikrein in arterial and venous thrombosis. As congenital deficiencies of factor XII (FXII) or prekallikrein (PK), the zymogens of FXIIa and α-kallikrein respectively, do not cause bleeding disorders, inhibition of these enzymes may have therapeutic benefit without compromising hemostasis. The relative contributions of FXIIa and α-kallikrein to thrombosis in animal models are not clear. We compared mice lacking FXII or PK to wild type mice in established models of arterial thrombosis. Wild type mice developed carotid artery occlusion when the vessel was exposed to a 3.5{\%} solution of ferric chloride (FeCl3). FXII-deficient mice were resistant to occlusion at 5{\%} FeCl3 and partially resistant at 10{\%} FeCl3. PK-deficient mice were resistant at 3.5{\%} FeCl3 and partially resistant at 5{\%} FeCl3. Mice lacking high molecular weight kininogen, a cofactor for PK activation and activity, were also partially resistant to thrombosis at 5{\%} FeCl3. Induction of carotid artery thrombosis with Rose Bengal was delayed in FXII-deficient mice compared to wild type or PK-deficient animals. In human plasma supplemented with silica, DNA or collagen to induce contact activation, an antibody to the FXIIa active site was more effective at preventing thrombin generation than an antibody to the α-kallikrein active site. Similarly, the FXIIa antibody was more effective at reducing fibrin formation in human blood flowing through collagen coated-tubes. The findings suggest that inhibitors of FXIIa will have more potent anti-thrombotic effects than inhibitors of α-kallikrein.",
    keywords = "Factor XII, Factor XIIa, Prekallikrein, Thrombosis, α-Kallikrein",
    author = "Yasin Kokoye and Ivan Ivanov and Qiufang Cheng and Anton Matafonov and Dickeson, {S. Kent} and Shauna Mason and Sexton, {Daniel J.} and Thomas Renn{\'e} and Keith McCrae and Feener, {Edward P.} and David Gailani",
    year = "2016",
    month = "4",
    day = "1",
    doi = "10.1016/j.thromres.2016.02.020",
    language = "English",
    volume = "140",
    pages = "118--124",
    journal = "Thrombosis Research",
    issn = "0049-3848",
    publisher = "Elsevier Limited",

    }

    TY - JOUR

    T1 - A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation

    AU - Kokoye, Yasin

    AU - Ivanov, Ivan

    AU - Cheng, Qiufang

    AU - Matafonov, Anton

    AU - Dickeson, S. Kent

    AU - Mason, Shauna

    AU - Sexton, Daniel J.

    AU - Renné, Thomas

    AU - McCrae, Keith

    AU - Feener, Edward P.

    AU - Gailani, David

    PY - 2016/4/1

    Y1 - 2016/4/1

    N2 - Studies with animal models implicate the plasma proteases factor XIIa (FXIIa) and α-kallikrein in arterial and venous thrombosis. As congenital deficiencies of factor XII (FXII) or prekallikrein (PK), the zymogens of FXIIa and α-kallikrein respectively, do not cause bleeding disorders, inhibition of these enzymes may have therapeutic benefit without compromising hemostasis. The relative contributions of FXIIa and α-kallikrein to thrombosis in animal models are not clear. We compared mice lacking FXII or PK to wild type mice in established models of arterial thrombosis. Wild type mice developed carotid artery occlusion when the vessel was exposed to a 3.5% solution of ferric chloride (FeCl3). FXII-deficient mice were resistant to occlusion at 5% FeCl3 and partially resistant at 10% FeCl3. PK-deficient mice were resistant at 3.5% FeCl3 and partially resistant at 5% FeCl3. Mice lacking high molecular weight kininogen, a cofactor for PK activation and activity, were also partially resistant to thrombosis at 5% FeCl3. Induction of carotid artery thrombosis with Rose Bengal was delayed in FXII-deficient mice compared to wild type or PK-deficient animals. In human plasma supplemented with silica, DNA or collagen to induce contact activation, an antibody to the FXIIa active site was more effective at preventing thrombin generation than an antibody to the α-kallikrein active site. Similarly, the FXIIa antibody was more effective at reducing fibrin formation in human blood flowing through collagen coated-tubes. The findings suggest that inhibitors of FXIIa will have more potent anti-thrombotic effects than inhibitors of α-kallikrein.

    AB - Studies with animal models implicate the plasma proteases factor XIIa (FXIIa) and α-kallikrein in arterial and venous thrombosis. As congenital deficiencies of factor XII (FXII) or prekallikrein (PK), the zymogens of FXIIa and α-kallikrein respectively, do not cause bleeding disorders, inhibition of these enzymes may have therapeutic benefit without compromising hemostasis. The relative contributions of FXIIa and α-kallikrein to thrombosis in animal models are not clear. We compared mice lacking FXII or PK to wild type mice in established models of arterial thrombosis. Wild type mice developed carotid artery occlusion when the vessel was exposed to a 3.5% solution of ferric chloride (FeCl3). FXII-deficient mice were resistant to occlusion at 5% FeCl3 and partially resistant at 10% FeCl3. PK-deficient mice were resistant at 3.5% FeCl3 and partially resistant at 5% FeCl3. Mice lacking high molecular weight kininogen, a cofactor for PK activation and activity, were also partially resistant to thrombosis at 5% FeCl3. Induction of carotid artery thrombosis with Rose Bengal was delayed in FXII-deficient mice compared to wild type or PK-deficient animals. In human plasma supplemented with silica, DNA or collagen to induce contact activation, an antibody to the FXIIa active site was more effective at preventing thrombin generation than an antibody to the α-kallikrein active site. Similarly, the FXIIa antibody was more effective at reducing fibrin formation in human blood flowing through collagen coated-tubes. The findings suggest that inhibitors of FXIIa will have more potent anti-thrombotic effects than inhibitors of α-kallikrein.

    KW - Factor XII

    KW - Factor XIIa

    KW - Prekallikrein

    KW - Thrombosis

    KW - α-Kallikrein

    UR - http://www.scopus.com/inward/record.url?scp=84959465130&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84959465130&partnerID=8YFLogxK

    U2 - 10.1016/j.thromres.2016.02.020

    DO - 10.1016/j.thromres.2016.02.020

    M3 - Article

    VL - 140

    SP - 118

    EP - 124

    JO - Thrombosis Research

    JF - Thrombosis Research

    SN - 0049-3848

    ER -